Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0432222 (SEM)
 47,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Toxicity Index scores were computed from symptoms, laboratory abnormalities, and hospitalizations attributed to nonsteroidal antiinflammatory drug (NSAID) therapy in 2,747 patients with rheumatoid arthritis receiving 5,642 courses of 11 NSAIDs over 8,481 patient-years. Substantial differences in overall toxicity were found, the differences between drugs often being clinically significant (2-3 times as toxic) and highly statistically significant. The results strengthened after adjustment for differing patient characteristics, held generally across multiple ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) data bank centers, and persisted after use of different techniques for the weighting of side effects. The most toxic side effects were experienced by patients taking indomethacin (mean +/- SEM score 3.99 +/- 0.58), tolmetin sodium (3.96 +/- 0.74), and meclofenamate sodium (3.86 +/- 0.66). Least toxic were coated or buffered aspirin (1.19 +/- 0.10), salsalate (1.28 +/- 0.34), and ibuprofen (1.94 +/- 0.43). The most toxic drugs were generally taken in the lowest relative doses. There are statistical differences in overall toxicity between different NSAIDs as used in rheumatoid arthritis, and these differences are both clinically and statistically significant.
 ...
PMID:The relative toxicity of nonsteroidal antiinflammatory drugs. 195 13

The authors sought to determine whether the self-report questionnaire developed by L.F. Callahan and T. Pincus is of use for the diagnosis of fibromyalgia when severe and/or chronic pain raises doubts as to an inflammatory rheumatic disease. This questionnaire evaluates the ratio between pain severity assessed on a visual analog scale and impairment of activities of daily living. High values suggest fibromyalgia, whereas low values occur in rheumatoid arthritis patients. The French translation of the questionnaire was completed by 15 fibromyalgia patients and 22 patients with inflammatory arthritic syndrome of whom 15 had rheumatoid arthritis. Mean pain/impairment ratio was 5.85 +/- 0.68 (SEM) in the fibromyalgia group versus 3.01 +/- 0.38 in the inflammatory rheumatism group. This difference was highly significant (p = 0.001 by Student's t test). The rheumatoid arthritis subgroup was also significantly different from the fibromyalgia group (p = 0.003). These findings are very similar to those reported by Callahan and Pincus. Our data confirm the value of this simple self-evaluation tool. In practice, ratios greater than 5 suggest fibromyalgia whereas ratios under 3 support the diagnosis of rheumatoid arthritis.
 ...
PMID:[Value of the self-evaluation of functional and painful disorders for the differentiation between fibromyalgia and inflammatory rheumatic diseases]. 814 49

The aim of this study was to analyze the renal outcome of pediatric lupus nephritis in the past two decades. We retrospectively reviewed the medical records of patients who fulfilled the 1987 American Rheumatism Association revised criteria for systemic lupus erythematosus who were followed up at the National Taiwan University Hospital between 1980 and 2001. All new patients who were under 18 years of age at the time of diagnosis were enrolled and were followed up until death, loss to follow-up, or till the end of 2002. The response to the treatment and renal outcome were analyzed. Seventy-two children (64 girls and 8 boys) were enrolled in the study. The mean age at diagnosis was 13.93+/-0.35 years (mean +/- SEM). The mean duration of follow-up was 7.12+/-0.51 years. The 5-year renal survival rate (survival without dialysis or transplantation) was 63.13% and the 10-year survival rate was 53.54%. It was significantly better in patients receiving cyclophosphamide (CYC) pulse therapy. The 5-year survival rate for these patients was 87.82% and the 10-year survival rate was 81.06%. The renal survival curve was better in the CYC pulse therapy group than in the no CYC pulse therapy group, with p=0.0022. The duration between the diagnosis of lupus nephritis and end-stage renal disease (ESRD) was significantly longer in the CYC group (9.66+/-1.32 yrs) than in the no CYC group (3.24+/-0.94 yers), p=0.036. In the multivariate analysis, risk factors of developing ESRD were failure to achieve complete remission, higher serum creatinine at the initiation of treatment, and not receiving CYC pulse therapy. The renal survival was significantly better in the CYC pulse therapy group. The CYC pulse therapy was recommended in pediatric lupus nephritis patients and every effort should be made to achieve complete remission.
 ...
PMID:Retrospective analysis of the renal outcome of pediatric lupus nephritis. 1529 92